TCIM
PGNX

TIAA CREF Investment Management’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

TIAA CREF Investment Management’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$1.51M Buy
326,593
+13,489
+4% +$61K ﹤0.01% 2135
2018
Q4 		$1.31M Hold
313,104
– – ﹤0.01% 2177
2018
Q3 		$1.96M Sell
313,104
-132,883
-30% -$1.02M ﹤0.01% 2127
2018
Q2 		$3.59M Buy
445,987
+116,450
+35% +$889K ﹤0.01% 1838
2018
Q1 		$2.46M Sell
329,537
-6,046
-2% -$40.2K ﹤0.01% 2002
2017
Q4 		$2M Sell
335,583
-138,301
-29% -$840K ﹤0.01% 2135
2017
Q3 		$3.49M Buy
473,884
+190,906
+67% +$1.21M ﹤0.01% 1846
2017
Q2 		$1.92M Buy
282,978
+91,437
+48% +$675K ﹤0.01% 2208
2017
Q1 		$1.81M Sell
191,541
-10,897
-5% -$109K ﹤0.01% 2197
2016
Q4 		$1.75M Sell
202,438
-87,518
-30% -$647K ﹤0.01% 2252
2016
Q3 		$1.83K Buy
289,956
+29,984
+12% +$181K ﹤0.01% 2225
2016
Q2 		$1.1M Buy
259,972
+44,797
+21% +$216K ﹤0.01% 2462
2016
Q1 		$938K Sell
215,175
-11,225
-5% -$50K ﹤0.01% 2509
2015
Q4 		$1.39M Sell
226,400
-23,449
-9% -$154K ﹤0.01% 2374
2015
Q3 		$1.43M Buy
249,849
+8,609
+4% +$66.1K ﹤0.01% 2353
2015
Q2 		$1.8M Sell
241,240
-34,008
-12% -$206K ﹤0.01% 2370
2015
Q1 		$1.65M Buy
275,248
+6,608
+2% +$41.6K ﹤0.01% 2341
2014
Q4 		$2.03M Sell
268,640
-26,284
-9% -$157K ﹤0.01% 2219
2014
Q3 		$1.53M Sell
294,924
-9,577
-3% -$47.7K ﹤0.01% 2389
2014
Q2 		$1.31M Buy
304,501
+79,505
+35% +$304K ﹤0.01% 2558
2014
Q1 		$920K Sell
224,996
-6,800
-3% -$34.8K ﹤0.01% 2685
2013
Q4 		$1.24M Hold
231,796
– – ﹤0.01% 2548
2013
Q3 		$1.17M Buy
231,796
+41,737
+22% +$226K ﹤0.01% 2529
2013
Q2 		$848K Buy
+190,059
New +$853K ﹤0.01% 2672

Other funds holding PGNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
PA
Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

TIAA CREF Investment Management's PGNX Position: Q1 2019 in Review

TIAA CREF Investment Management increased its Progenics Pharmaceuticals Inc (PGNX) stake by 4.3% in Q1 2019, buying an estimated $61K and bringing the position to 326,593 shares worth $1.51M. The position accounts for ﹤0.01% of the portfolio, ranked #2135.

TIAA CREF Investment Management first reported a position in PGNX in Q2 2013 and has held it in 24 quarters since. The position peaked at $3.59M in Q2 2018. 148 funds tracked by Wall St. Rank hold PGNX as of Q1 2019.

  • TIAA CREF Investment Management held 326,593 shares of Progenics Pharmaceuticals Inc worth $1.51M as of Q1 2019.
  • TIAA CREF Investment Management bought 13,489 Progenics Pharmaceuticals Inc shares in Q1 2019, an estimated $61K.
  • Progenics Pharmaceuticals Inc made up ﹤0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #2135 holding.
  • TIAA CREF Investment Management first reported a position in Progenics Pharmaceuticals Inc in Q2 2013 and has held it in 24 quarters since.
  • TIAA CREF Investment Management's Progenics Pharmaceuticals Inc position peaked at $3.59M in Q2 2018.
  • 148 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.